Because some previous studies suggested that the treatment response of highly malignant breast cancers, namely, HER2-enriched breast cancer and TNBC, is related to the number of tumor-infiltrating lymphocytes, both are considered to have high immunoactivity [24–27]. Here, ERBB2 is linked to breast cancer.